Novartis buys into superbug drug.

Fonction NEWS

[ILLUSTRATION OMITTED]

Novartis has bought U.S.-based Protez Pharmaceuticals in a deal worth up to SFr 415 million ($400 million), giving it rights to an antibiotic that could be used to fight 'superbugs' such as the MRSA bacterial infection, the Swiss drugmaker said.

Novartis said the antibiotic known as PZ-601 would strengthen its range of specialty medicines to combat hospital infections caused by even the most drug-resistant bacteria, including MRSA (Methicillin-resistant Staphylococcus aureus).

PZ-601 is a novel...

Pour continuer la lecture

SOLLICITEZ VOTRE ESSAI

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT